1. Scrip

BIO-Europe Spring 2019: InteRNA Sees MicroRNA Potential In Cancer Therapy

 
• By Mike Ward

Roel Schaapveld is CEO of Dutch microRNA specialist InteRNA Technologies. He spoke to Mike Ward about the company’s therapeutic approach.

Video interview
Roel Schaapveld Describe's InteRNA's work in miRNA

MicroRNAs each regulate multiple messenger RNAs in the body. InteRNA Technologies aims to develop improved treatments for cancer by harnessing microRNAs, or miRNAs, as therapeutics with more than one mode of action. CEO Roel Schaapveld discussed the company’s work, the challenges it still faces, and its preparations to enter clinical development.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.